ESTERO, FLORIDA — October 3, 2025 — Leads & Copy — Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) announced that Interim CEO Kraig Higginson will present and participate in 1×1 meetings at the Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference.
The presentation will feature updates on the company’s pipeline progress and key milestones expected throughout the remainder of 2025 and early 2026. Aspire is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology.
The company anticipates key milestones to be discussed including an H2 2025 target submission of New Drug Application (NDA) for Sublingual High-dose Aspirin (Lead Program) and an H1 2026 finalization of formulation and manufacture test product for Sublingual ED medication.
Virtual Presentation – Wednesday, October 8th at 1:00 p.m. Eastern
Virtual 1×1 Meetings – Wednesday, October 8th and Thursday, October 9th
Format – Corporate presentations with fireside-style Q&A sessions proctored by Noble’s analysts and bankers, along with scheduled 1×1 meetings with qualified investors
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements. “We don’t make the drugs…We make them work better for your body”.
Contact:
Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com
James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com
Source: Aspire Biopharma Holdings, Inc.
